Austrian biotech Marinomed is weighing up strategic options for its virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo, Reckitt and Procter & Gamble for use in OTC nasal sprays.
Marinomed Exploring Options For Virus-Blocking OTC Nasal Spray Platform
The virus-blocking platform used in OTC nasal sprays marketed by Perrigo and Reckitt, amongst others, developed by Austria's Marinomed is up for sale.
More from Strategy
• By
Wellnex bringing brands such as Pain Away, Wakey Wakey and Nighty Night to UK market shortly after gaining admission to the the AIM market of the London Stock Exchange.
• By
A round-up of the latest European health & wellness market moves: Maxwellia names chief operating officer; Nestle appoints marketing & sales head; Alland & Robert gets deputy general manager.
• By
Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.
• By
The homeopathy specialist reported a big decline in profits in 2024 as a move to restructure its ailing French operation hit the bottom line.